Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group1:Participants in the intervention group will receive Vonoprazan (20 milligrams, twice daily), Amoxicillin (1,000 milligrams, twice daily), and Clarithromycin (500 mi
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age greater than 18 years Confirmed diagnosis of Helicobacter pylori infection based on standard methods (Urea Breath Test, Stool Antigen Test, or Histopathological Evidence) Informed consent for study participation
Exclusion criteria
Exclusion criteria: History of severe hypersensitivity to Vonoprazan, Proton Pump Inhibitors, or the antibiotics used in the protocol. Severe hepatic or renal impairment (for example, renal impairment with creatinine clearance less than thirty milliliters per minute or hepatic impairment Child-Pugh Class C) Pregnancy, breastfeeding, or failure to use effective contraception in women of childbearing potential. Concomitant use of medications with significant known interactions with the study drugs Participation in another clinical trial within the past 4 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication success rate. Timepoint: The outcome evaluation will be conducted in two stages: the first stage, prior to the intervention’s commencement (Baseline), and the second stage, 8 weeks after the complete cessation of the intervention period. Method of measurement: The Urea Breath Test with Carbon-13 (¹³C-UBT) or the Fecal Antigen Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Asad Hashemi
Oroumia University of Medical Sciences
Outcome results
None listed